ClinicalTrials.gg
CompletedNCT02347072Updated Apr 19, 2017Results posted

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

A Phase 3 interventional study of GFF MDI (PT003) and Placebo MDI in COPD, sponsored by Pearl Therapeutics, Inc.. Completed. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-19.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
47th of 73
80 · median 152
Started
2015
with 7 others
Phase 3
33 of 73
1 open now
Registered
45th of 73
by date
Lead sponsor
18 of 73
Pearl Therapeutics, Inc.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 47th largest by enrollment, is one of 8 that started in 2015, is one of 33 in phase 3, and was the 45th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 40 years of age and no older than 80 at Screening
  • Women of non-child bearing potential or negative serum pregnancy test at Screening, and agrees to acceptable methods used consistently and correctly Screening until 14 days after final visit.
  • Subjects with an established clinical history of as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
  • Current or former smokers with a history of at least 10 pack-years of cigarette smoking
  • Pre- and post-bronchodilator /FVC ratio of \<0.70
  • Post-bronchodilator FEV1 must be \<80% predicted normal value, calculated using NHANES III reference equations, and the measured FEV1 must also be ≥750 mL if FEV1 \<30% of predicted normal value.

Exclusion criteria

Exclusion Criteria:

  • Significant diseases other than , i.e., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
  • Women who are pregnant or lactating.
  • Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.
  • Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Screening or during the Screening Period.
  • Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral or antibiotics within 6 weeks prior to Screening or during the Screening Period.
  • Subjects who have uncontrolled hypertension.
  • Subjects who have cancer that has not been in complete remission for at least five years.
  • Subjects with abnormal liver function tests defined as , ALT, or total ≥1.5 times at Screening and on repeat testing.
  • Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of whether or not they have been treated. Subjects with a diagnosis of open angle glaucoma who have intraocular pressure controlled with medication(s) are eligible.
  • Subjects with symptomatic prostatic hypertrophy that is clinically significant in the opinion of the Investigator. Subjects with a trans-urethral resection of prostate (TURP) or full resection of the prostate within 6 months prior to Screening are excluded from the study.
  • Subjects with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    GFF MDI (PT003)

    Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

    Drug: GFF MDI (PT003)

  • Placebo comparator
    Placebo MDI

    Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

    Drug: Placebo MDI

  • Active comparator
    Spiriva® Respimat® (Tiotropium Bromide)

    Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)

    Drug: Spiriva® Respimat® (Tiotropium Bromide)

Interventions

  • DrugGFF MDI (PT003)

    Drug pages: Glycopyrrolate · Formoterol

    Also known as: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

  • DrugPlacebo MDI

    Also known as: Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

  • Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24

    Normalized Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-24

    Time frame: Pre dose, 15 and 30 minutes, 1, 2, 4, 8, 12, 12.25, 12.5, 13, 14, 16, 22, and 24 hours post the morning dose on Day 29

Secondary outcomes

  1. FEV1 AUC12-24

    Normalized FEV1 AUC12-24

    Time frame: Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the evening dose on Day 29

  2. FEV1 AUC0-12

    Normalized FEV1 AUC0-12

    Time frame: Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the morning dose on Day 29

  3. Peak Change From Baseline in FEV1 Evening

    Peak Change From Baseline in FEV1 Evening

    Time frame: Baseline and Day 29

  4. Peak Change From Baseline in FEV1 Morning

    Peak Change From Baseline in FEV1 Morning

    Time frame: Baseline and Day 29

  5. Morning Pre-Dose Trough FEV1 on Day 29

    Morning Pre-Dose Trough FEV1 on Day 29

    Time frame: Day 29

  6. Morning Pre-Dose Trough FEV1 on Day 30

    Morning Pre-Dose Trough FEV1 on Day 30

    Time frame: Day 30

  7. Peak Change From Baseline in IC (Inspiratory Capacity) Evening

    Peak Change From Baseline in IC Evening

    Time frame: Baseline and Day 29

  8. Peak Change From Baseline in IC Morning

    Peak Change From Baseline in IC Morning

    Time frame: Baseline and Day 29

07

Results

Posted Apr 19, 2017

Participant flow

This study was conducted at 10 sites in the US from February 2015 to August 2015. The study was anticipated to run for approximately 9 months but not expected to exceed 12 months.

Participant flow — Overall Study
MilestoneOverall Study
Started80
Gff mdi 14.4/9.6 µg75
Placebo mdi72
Spiriva respimat 5 µg73
Completed62
Not completed18
Withdrew: Adverse event2
Withdrew: Withdrawal by subject6
Withdrew: Physician decision1
Withdrew: Lost to follow-up2
Withdrew: Protocol violation1
Withdrew: Disc due to protocol-specified criteria6

Outcome measures

PrimaryForced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24

Normalized Forced Expiratory Volume in 1 second (FEV1) Area Under the Curve (AUC) 0-24

Time frame:
Pre dose, 15 and 30 minutes, 1, 2, 4, 8, 12, 12.25, 12.5, 13, 14, 16, 22, and 24 hours post the morning dose on Day 29
Reported as:
Least squares mean · Liters
Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-24
LitersGFF MDISpiriva RespimatPlacebo
Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) 0-240.192 (0.141 to 0.243)0.112 (0.061 to 0.162)-0.072 (-0.123 to -0.022)
SecondaryFEV1 AUC12-24

Normalized FEV1 AUC12-24

Time frame:
Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the evening dose on Day 29
Reported as:
Least squares mean · Liters
FEV1 AUC12-24
LitersGFF MDISpiriva RespimatPlacebo
FEV1 AUC12-240.159 (0.104 to 0.214)0.039 (-0.015 to 0.094)-0.118 (-0.173 to -0.063)
SecondaryFEV1 AUC0-12

Normalized FEV1 AUC0-12

Time frame:
Pre dose, 15 and 30 minutes, 1, 2, 4, 8, and 12 hours post the morning dose on Day 29
Reported as:
Least squares mean · Liters
FEV1 AUC0-12
LitersGFF MDISpiriva RespimatPlacebo
FEV1 AUC0-120.226 (0.175 to 0.276)0.178 (0.127 to 0.228)-0.026 (-0.077 to 0.025)
SecondaryPeak Change From Baseline in FEV1 Evening

Peak Change From Baseline in FEV1 Evening

Time frame:
Baseline and Day 29
Reported as:
Least squares mean · Liters
Peak Change From Baseline in FEV1 Evening
LitersGFF MDISpiriva RespimatPlacebo
Peak Change From Baseline in FEV1 Evening0.395 (0.334 to 0.456)0.230 (0.170 to 0.291)0.058 (-0.003 to 0.119)
SecondaryPeak Change From Baseline in FEV1 Morning

Peak Change From Baseline in FEV1 Morning

Time frame:
Baseline and Day 29
Reported as:
Least squares mean · Liters
Peak Change From Baseline in FEV1 Morning
LitersGFF MDISpiriva RespimatPlacebo
Peak Change From Baseline in FEV1 Morning0.406 (0.351 to 0.462)0.325 (0.270 to 0.381)0.129 (0.073 to 0.185)
SecondaryMorning Pre-Dose Trough FEV1 on Day 29

Morning Pre-Dose Trough FEV1 on Day 29

Time frame:
Day 29
Reported as:
Least squares mean · Liters
Morning Pre-Dose Trough FEV1 on Day 29
LitersGFF MDISpiriva RespimatPlacebo
Morning Pre-Dose Trough FEV1 on Day 290.140 (0.095 to 0.185)0.097 (0.053 to 0.142)-0.020 (-0.066 to 0.025)
SecondaryMorning Pre-Dose Trough FEV1 on Day 30

Morning Pre-Dose Trough FEV1 on Day 30

Time frame:
Day 30
Reported as:
Least squares mean · Liters
Morning Pre-Dose Trough FEV1 on Day 30
LitersGFF MDISpiriva RespimatPlacebo
Morning Pre-Dose Trough FEV1 on Day 300.129 (0.073 to 0.185)0.072 (0.015 to 0.128)-0.073 (-0.130 to -0.017)
SecondaryPeak Change From Baseline in IC (Inspiratory Capacity) Evening

Peak Change From Baseline in IC Evening

Time frame:
Baseline and Day 29
Reported as:
Least squares mean · Liters
Peak Change From Baseline in IC (Inspiratory Capacity) Evening
LitersGFF MDISpiriva RespimatPlacebo
Peak Change From Baseline in IC (Inspiratory Capacity) Evening0.421 (0.343 to 0.498)0.297 (0.221 to 0.372)0.109 (0.032 to 0.186)
SecondaryPeak Change From Baseline in IC Morning

Peak Change From Baseline in IC Morning

Time frame:
Baseline and Day 29
Reported as:
Least squares mean · Liters
Peak Change From Baseline in IC Morning
LitersGFF MDISpiriva RespimatPlacebo
Peak Change From Baseline in IC Morning0.454 (0.388 to 0.520)0.374 (0.307 to 0.440)0.206 (0.139 to 0.273)

Adverse events

Collected over Adverse events were collected from the time the subject signed consent up to the follow-up phone call 7-14 days after last dose of study drug.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GFF MDI—2/75 (2.7%)5/75 (6.7%)
Spiriva Respimat—2/73 (2.7%)5/73 (6.8%)
Placebo—2/72 (2.8%)6/72 (8.3%)
Most frequent serious events
Most frequent serious events
EventGFF MDISpiriva RespimatPlacebo
Atrial fibrillationCardiac disorders0/750/731/72
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/750/731/72
Small intestinal obstructionGastrointestinal disorders0/750/731/72
Acute Myocardial InfarctionCardiac disorders0/751/730/72
Chest painGeneral disorders0/751/730/72
InfluenzaInfections and infestations1/750/730/72
PneumoniaInfections and infestations1/750/730/72
SepsisInfections and infestations1/750/730/72
Most frequent other events
Most frequent other events
EventGFF MDISpiriva RespimatPlacebo
VomitingGastrointestinal disorders0/753/730/72
TremorNervous system disorders3/750/730/72
HeadacheNervous system disorders1/751/732/72
CoughRespiratory, thoracic and mediastinal disorders1/751/732/72
Back painMusculoskeletal and connective tissue disorders1/750/732/72
FuruncleInfections and infestations0/752/730/72
ConstipationGastrointestinal disorders2/750/731/72

Baseline characteristics

MITT population was a subset of the ITT Population including subjects who received treatment and had post treatment efficacy data from at least 2 treatment periods and this population is used for baseline characteristics. Participant Flow includes all patients randomized, regardless of treatment received.

Age, Continuous
Age, Continuous(Years)All Subjects
Mean61.8 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female48
Male27
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Reisner C, Gottschlich G, Fakih F, Koser A, Krainson J, Delacruz L, Arora S, Feldman G, Pudi K, Siddiqui S, Orevillo C, Maes A, St Rose E, Martin U. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Respir Res. 2017 Aug 18;18(1):157. doi: 10.1186/s12931-017-0636-4. PubMed 28821260 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Aug 2015, 6 months.

Results were first posted in Apr 2017, 1 year 8 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 6 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2015
First posted
Jan 27, 2015
StartActual
Feb 1, 2015
Primary completionActual
Aug 1, 2015
CompletionActual
Mar 1, 2016
Results first posted
Apr 19, 2017
Last update
Apr 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02347072
Responsible party
Sponsor
First posted
Jan 27, 2015
Start date
Feb 1, 2015
Primary completion
Aug 1, 2015
Completion
Mar 1, 2016
Results posted
Apr 19, 2017
Last update
Apr 19, 2017

Study contacts

Colin Reisner, MD
study chair · Pearl Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Formoterol

Start the discussion